相关实验视频
Updated: Jun 6, 2025

06:21
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
32
一种增强的生物活性奇托改性微乳液,用于性结肠炎的粘膜愈合
Lixia Yue1, Ping Ye2, Yi Zhang3
1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
International journal of biological macromolecules
|November 24, 2024
概括
携带nobiletin的基托桑修饰微乳液有效地穿透肠道粘液屏障. 这种向的输送增强了细胞吸收,改善了治疗性结肠炎的药物生物可用性.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 肠道粘液层对全身药物吸收构成重大障碍.
- 有效的性结肠炎 (UC) 治疗需要将药物直接输送到结肠.
- 自然的小分子提供治疗潜力,但面临着交付挑战.
研究的目的:
- 设计一种新型的基托改性微乳液 (CS-ME),用于向向结肠输送诺比素 (NOB).
- 评估NOB-CS-ME克服肠粘液屏障的能力.
- 评估NOB-CS-ME在UC中增强的细胞吸收和潜在的治疗疗效.
主要方法:
- 包装nobiletin (NOB-CS-ME) 的微乳液的基托修饰.
- 关于粒子大小和表面电荷的NOB-CS-ME的表征.
- 在体外评估粘液的透和逃逸.
- 结肠上皮细胞对细胞吸收的评估.
主要成果:
- NOB-CS-ME 显示与肠粘液层的相互作用减少,从而促进屏障逃逸.
- NOB-CS-ME 呈现出显著增强的结肠上皮细胞细胞吸收 (约. 与未经修改的微乳液相比,增加了1.3倍).
- 工程系统显示了提高药物的生物可用性的潜力.
结论:
- 基托桑修饰的微乳液有效地克服了肠道粘液屏障,用于向药物输送.
- 增强的细胞吸收表明,在性结肠炎中改善了nobiletin的治疗潜力.
- 这种输送策略为UC治疗中的天然小分子药物提供了有希望的方法.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
390
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
390
Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
351
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
351
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74

